Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-reduced inotuzumab ozogamicin as bridging therapy before anti-CD19 CAR T cells in relapsed/refractory ALL
KCT0009690Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Pfizer. Started Aug 2024; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on KCT0009690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009690.